All Stories

  1. A Potential Role of Natural Bioactive Compounds Found in Food in the Prevention of Idiopathic Parkinson’s Disease
  2. On the Role of Iron in Idiopathic Parkinson’s Disease
  3. Why are neuromelanin-containing dopaminergic neurons lost in idiopathic Parkinson’s disease?
  4. Single-neuron neurodegeneration as a degenerative model for Parkinson’s disease
  5. A Preclinical Model for Parkinson’s Disease Based on Transcriptional Gene Activation via KEAP1/NRF2 to Develop New Antioxidant Therapies
  6. Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase
  7. Generation of nonviral integration-free human iPS cell line KISCOi001-A from normal human fibroblasts, under defined xeno-free and feeder-free conditions
  8. Cellular Trafficking of Glutathione Transferase M2-2 Between U373MG and SHSY-S7 Cells is Mediated by Exosomes
  9. State and perspectives on flavonoid neuroprotection against aminochrome-induced neurotoxicity
  10. The Flavonoid Agathisflavone from Poincianella pyramidalis Prevents Aminochrome Neurotoxicity
  11. The importance of choosing a preclinical model that reflects what happens in Parkinson's disease
  12. DT-Diaphorase Prevents Aminochrome-Induced Lysosome Dysfunction in SH-SY5Y Cells
  13. Can we conclude a potential therapeutic action for Parkinson’s disease by using postmortem tissue and a preclinical model based on an exogenous neurotoxin?
  14. P1‐159: RARE VARIANTS IN PLCG2, ABI3, AND TREM2 GENES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE IN AN ARGENTINIAN SAMPLE: IS IT A EUROPEAN HERITAGE?
  15. Comment on: “Activating Autophagy as a Therapeutic Strategy for Parkinson’s Disease”
  16. Aminochrome decreases NGF, GDNF and induces neuroinflammation in organotypic midbrain slice cultures
  17. Aminochrome Induces Irreversible Mitochondrial Dysfunction by Inducing Autophagy Dysfunction in Parkinson's Disease
  18. Neurotoxins as Preclinical Models for Parkinson’s Disease
  19. KM-34, a Novel Antioxidant Compound, Protects against 6-Hydroxydopamine-Induced Mitochondrial Damage and Neurotoxicity
  20. The Importance of Mitophagy in Maintaining Mitochondrial Function in U373MG Cells. Bafilomycin A1 Restores Aminochrome-Induced Mitochondrial Damage
  21. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
  22. Aminochrome induces microglia and astrocyte activation
  23. Knockdown of Myo-Inositol Transporter SMIT1 Normalizes Cholinergic and Glutamatergic Function in an Immortalized Cell Line Established from the Cerebral Cortex of a Trisomy 16 Fetal Mouse, an Animal Model of Human Trisomy 21 (Down Syndrome)
  24. Aminochrome as preclinical model for Parkinson's disease
  25. Commentary: Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?
  26. DT-diaphorase Protects Against Autophagy Induced by Aminochrome-Dependent Alpha-Synuclein Oligomers
  27. New preclinical model are required to discover neuroprotective compound in Parkinson’s disease
  28. On the Role of Mining Exposure in Epigenetic Effects in Parkinson’s Disease
  29. On the Role of DT-Diaphorase Inhibition in Aminochrome-Induced Neurotoxicity In Vivo
  30. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson’s Disease?
  31. Autophagy protects against neural cell death induced by piperidine alkaloids present in Prosopis juliflora (Mesquite)
  32. On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease
  33. Corrigendum: Commentary: Evaluation of Models of Parkinson's Disease
  34. DT-diaphorase protects astrocytes from aminochrome-induced toxicity
  35. Commentary: A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease
  36. Commentary: Evaluation of Models of Parkinson's Disease
  37. Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson’s disease
  38. Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases
  39. Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
  40. Erratum
  41. The need of a new and more physiological preclinical model for Parkinson’s disease
  42. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
  43. Aminochrome Toxicity is Mediated by Inhibition of Microtubules Polymerization Through the Formation of Adducts with Tubulin
  44. Neurotoxin Mechanisms and Processes Relevant to Parkinson’s Disease: An Update
  45. DT-Diaphorase Prevents Aminochrome-Induced Alpha-Synuclein Oligomer Formation and Neurotoxicity
  46. A new mechanism for protection of dopaminergic neurons mediated by astrocytes
  47. Molecular and Neurochemical Mechanisms Dopamine Oxidation To O-Quinones in Parkinson’s Disease Pathogenesis
  48. Glutathione Transferase-M2-2 Secreted from Glioblastoma Cell Protects SH-SY5Y Cells from Aminochrome Neurotoxicity
  49. Protective and toxic roles of dopamine in Parkinson's disease
  50. Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction
  51. Advances in Stem Cell Research for Parkinson Disease
  52. Dopamine and L-dopa as Selective Endogenous Neurotoxins
  53. Mechanisms of Dopamine Oxidation and Parkinson’s Disease
  54. RCSN Cell System for Identifying Dopaminergic Neurotoxicity
  55. One-Electron Reduction of 6-Hydroxydopamine Quinone is Essential in 6-Hydroxydopamine Neurotoxicity
  56. Frequency of the D620N Mutation in VPS35 in Parkinson Disease
  57. Erratum to: Protective Effects of Nicotine Against Aminochrome-Induced Toxicity in Substantia Nigra Derived Cells: Implications for Parkinson’s Disease
  58. Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity
  59. Protective Effects of Nicotine Against Aminochrome-Induced Toxicity in Substantia Nigra Derived Cells: Implications for Parkinson’s Disease
  60. Guidelines for the use and interpretation of assays for monitoring autophagy
  61. Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy
  62. The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1
  63. Dopamine Oxidation and Autophagy
  64. The role of metal ions in dopaminergic neuron degeneration in Parkinsonism and Parkinson’s disease
  65. Altered Voltage Dependent Calcium Currents in a Neuronal Cell Line Derived From the Cerebral Cortex of a Trisomy 16 Fetal Mouse, an Animal Model of Down Syndrome
  66. Lrrk2 p.Q1111H substitution and Parkinson’s disease in Latin America
  67. ChemInform Abstract: The Role of Metal Ions in Dopaminergic Neuron Degeneration in Parkinsonism and Parkinson′s Disease
  68. The role of metal ions in dopaminergic neuron degeneration in Parkinsonism and Parkinson’s disease
  69. Autophagy Protects Against Aminochrome-Induced Cell Death in Substantia Nigra-Derived Cell Line
  70. Catecholaminergic Cell Lines for the Study of Dopamine Metabolism and Neurotoxicity
  71. Association of Parkinson disease to PARK16 in a Chilean sample
  72. Stable Expression of Short Interfering RNA for DT-Diaphorase Induces Neurotoxicity
  73. Erratum to: Aminochrome Induces Disruption of Actin, Alpha-, and Beta-Tubulin Cytoskeleton Networks in Substantia-Nigra-Derived Cell Line
  74. Aminochrome Induces Disruption of Actin, Alpha-, and Beta-Tubulin Cytoskeleton Networks in Substantia-Nigra-Derived Cell Line
  75. Diagnóstico genético disponible para la enfermedad de huntington en chile
  76. IV Neurotoxicity Society Meeting: Neurochemical Mechanisms of Neurodegenerative Disorders
  77. Molecular and Neurochemical Mechanisms in PD Pathogenesis
  78. Copper·Dopamine Complex Induces Mitochondrial Autophagy Preceding Caspase-independent Apoptotic Cell Death
  79. Chapter 4 Molecular Aspects of Neurotoxins in Dopaminergic Neurons
  80. The catecholaminergic RCSN-3 cell line: A model to study dopamine metabolism
  81. Copper Neurotoxicity in Rat Substantia Nigra and Striatum Is Dependent on DT-Diaphorase Inhibition
  82. Erratum
  83. Effect of the knockdown of amyloid precursor protein on intracellular calcium increases in a neuronal cell line derived from the cerebral cortex of a trisomy 16 mouse
  84. Botulinum neurotoxin: Evolution from poison, to research tool - onto medicinal therapeutic and future pharmaceutical panacea
  85. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease
  86. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson’s disease
  87. Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component
  88. Inhibition of VMAT-2 and DT-Diaphorase Induce Cell Death in a Substantia Nigra-Derived Cell LineAn Experimental Cell Model for Dopamine Toxicity Studies
  89. Neurotoxins and neurotoxicity mechanisms. an overview
  90. Knockdown of amyloid precursor protein normalizes cholinergic function in a cell line derived from the cerebral cortex of a trisomy 16 mouse: An animal model of down syndrome
  91. Dopamine-Dependent Iron Toxicity in Cells Derived from Rat Hypothalamus
  92. Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra
  93. Cell Lines as In Vitro Models for Drug Screening and Toxicity Studies
  94. On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation
  95. Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor
  96. Neurotoxins and neurotoxic species implicated in neurodegeneration
  97. Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats
  98. Inhibition of DT-Diaphorase potentiates thein vivo neurotoxic effect of intranigral injection of salsolinol in rats
  99. MPP+-induced degeneration is potentiated by dicoumarol in cultures of the RCSN-3 dopaminergic cell line. Implications of neuromelanin in oxidative metabolism of dopamine neurotoxicity
  100. Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. A review
  101. Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra
  102. Establishment and characterization of immortalized neuronal cell lines derived from the spinal cord of normal and trisomy 16 fetal mice, an animal model of Down syndrome
  103. Neurotoxicological and neuroprotective elements in Parkinson’s disease
  104. Inhibition of DT-diaphorase is a requirement for Mn3+ to produce a 6-OH-dopamine like rotational behaviour
  105. Neurotoxicity of some MAO inhibitors in adult rat hypothalamic cell culture
  106. Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line
  107. Possible Role of Salsolinol Quinone Methide in the Decrease of RCSN-3 Cell Survival
  108. THE PRICE OF DEVELOPMENT IN CHILE
  109. The possible role of one-electron reduction of aminochrome in the neurodegenerative process of the dopaminergic system
  110. Glutathione Transferase M2-2 Catalyzes Conjugation of Dopamine and Dopa o-Quinones
  111. Reduction of Brain Antioxidant Defense Upon Treatment with Butylated Hydroxyanisole (BHA) and Sudan III in Syrian Golden Hamster
  112. Regioselectivity and Reversibility of the Glutathione Conjugation of Quercetin Quinone Methide
  113. Role of redox cycling and activation by DT-diaphorase in the cytotoxicity of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB-1954) and its analogs
  114. Interplay Between CYP3A-Mediated Metabolism and Polarized Efflux of Terfenadine and Its Metabolites in Intestinal Epithelial Caco-2 (TC7) Cell Monolayers
  115. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product
  116. DT-diaphorase catalyzes N-denitration and redox cycling of tetryl
  117. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects
  118. Quantitative structure activity relationships for the conversion of nitrobenzimidazolones and nitrobenzimidazoles by DT-diaphorase: implications for the kinetic mechanism
  119. Nitrobenzimidazoles as Substrates for DT-Diaphorase and Redox Cycling Compounds: Their Enzymatic Reactions and Cytotoxicity
  120. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes
  121. Effects of Four Organohalogen Environmental Contaminants on Cytochrome P450 Forms That Catalyze 4- and 2-Hydroxylation of Estradiol in the Rat Liver
  122. Human Class Mu Glutathione Transferases, in Particular Isoenzyme M2-2, Catalyze Detoxication of the Dopamine Metabolite Aminochrome
  123. The two-electron quinone reductase DT-diaphorase generates and maintains the antioxidant (reduced) form of coenzyme Q in membranes
  124. DT-Diaphorase Maintains the Reduced State of Ubiquinones in Lipid Vesicles thereby Promoting their Antioxidant Function
  125. Peroxidase Activity of Liver Microsomal Vitamin D 25-Hydroxylase and Cytochrome P450 1A2 Catalyzes 25-Hydroxylation of Vitamin D3and Oxidation of Dopamine to Aminochrome
  126. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems.
  127. Effects of Superoxide Dismutase and Catalase during Reduction of Adrenochrome by DT-Diaphorase and NADPH-Cytochrome P450 Reductase
  128. Studies on the mode of action of the herbicidal effect of 2,4,5-trichlorophenoxyacetic acid on germinating Norway spruce
  129. Superoxide Dismutase and Catalase Enhance Autoxidation during One-Electron Reduction of Aminochrome by NADPH-Cytochrome P-450 Reductase
  130. Superoxide dismutase and catalase prevent the formation of reactive oxygen species during reduction of cyclized dopa ortho-quinone by DT-diaphorase
  131. The protective effect of superoxide dismutase and catalase against formation of reactive oxygen species during reduction of cyclized norepinephrine ortho-quinone of DT-diaphorase
  132. Activity and immunohistochemistry of DT-diaphorase in hamster and human kidney tumours
  133. A new direct method for determining superoxide dismutase activity by measuring hydrogen peroxide formation
  134. The Effect of 5OH-1,4-Naphthoquinone on Norway Spruce Seeds during Germination
  135. The cytotoxic effects of 5-OH-1,4-naphthoquinone and 5,8-diOH-1,4-naphthoquinone on doxorubicin-resistant human leukemia cells (HL-60)
  136. Separation and characterization of isoforms of DT-diaphorase from rat liver cytosol
  137. Oxygen toxicity in the nervous tissue: Comparison of the antioxidant defense of rat brain and sciatic nerve
  138. Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve
  139. The levels of quinone reductases, superoxide dismutase and glutathione-related enzymatic activities in diethylstilbestrol-induced carcinogenesis in the kidney of male Syrian golden hamsters
  140. On the mechanism of the Mn3+-induced neurotoxicity of dopamine: Prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase
  141. DT-diaphorase-catalyzed two-electron reduction of various p-benzoquinone- and 1,4-naphthoquinone epoxides
  142. Effect of superoxide dismutase on the autoxidation of various hydroquinones—A possible role of superoxide dismutase as a superoxide: Semiquinone oxidoreductase
  143. DT-diaphorase-catalyzed two electron reduction of quinone epoxides
  144. Dicoumarol-sensitive glucuronidation of benzo(a)pyrene metabolites in rat liver microsomes